Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)
This article was originally published in PharmAsia News
Executive Summary
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
You may also be interested in...
Sanofi Targets 18 Drug Launches From 2012 To 2015
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker